{"id":"W4399122099","doi":"10.1200/jco.2024.42.16_suppl.1007","title":"Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Eisai Canada","keywords":"Medicine; Pertuzumab; Trastuzumab; Eribulin; Taxane; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Paclitaxel; Anthracycline; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003399726,0.001600616,0.002581888,0.0006003287,0.0004057099,0.0009956155,0.001068743,0.001627296,0.004082777],"category_scores_gemma":[0.001627272,0.0007677191,0.002032017,0.0005794968,0.001483344,0.001297823,0.0004688712,0.003216636,0.0006807126],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009084421,"about_ca_system_score_gemma":0.001328533,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006453638,"about_ca_topic_score_gemma":0.002365657,"domain_scores_codex":[0.9989617,0.0006992232,0.00005864678,0.0001069096,0.00005818262,0.0001153784],"domain_scores_gemma":[0.998968,0.0002119665,0.0002407596,0.00009799057,0.00005010088,0.0004311199],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9573174,0.01720934,0.0007386457,0.0003686549,0.000942781,0.00004112919,0.00004849495,0.0003552902,0.004750836,0.00009133556,0.000896152,0.01724003],"study_design_scores_gemma":[0.8869687,0.1095782,0.001536101,0.00002155013,0.0004605514,0.00003781415,0.00001365147,0.0002635865,0.0004935215,0.00007622993,0.0005388946,0.00001096315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896837,0.00395958,0.0004626623,0.0006062454,0.0003753783,0.002715053,0.0006917462,0.00006503378,0.001440542],"genre_scores_gemma":[0.986754,0.003253232,0.001768571,0.001151224,0.0004939932,0.002747982,0.001557889,0.00002786757,0.002245248],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004082777,"threshold_uncertainty_score":0.01797968,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.117627131079345,"score_gpt":0.5248258775869272,"score_spread":0.4071987465075822,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}